Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:CYPH NASDAQ:FBRX NASDAQ:GALT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.55-0.6%$2.68$1.65▼$4.00$260.54M1.59299,891 shs259,239 shsCYPHCypherpunk Technologies$0.64+3.1%$0.93$0.23▼$3.70$65.85M-0.027.08 million shs1.33 million shsFBRXForte Biosciences$21.03$22.35$9.10▼$35.80$292.11M2.87392,073 shs3.08 million shsGALTGalectin Therapeutics$4.97-0.4%$2.55$2.03▼$7.13$327.32M0.47915,842 shs6.47 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%+6.04%-4.32%-0.59%+26.62%CYPHCypherpunk Technologies0.00%-13.72%-43.56%+1.97%+143.81%FBRXForte Biosciences0.00%+17.82%+10.28%-20.10%+71.67%GALTGalectin Therapeutics0.00%+75.62%+97.22%+93.39%+113.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.55-0.6%$2.68$1.65▼$4.00$260.54M1.59299,891 shs259,239 shsCYPHCypherpunk Technologies$0.64+3.1%$0.93$0.23▼$3.70$65.85M-0.027.08 million shs1.33 million shsFBRXForte Biosciences$21.03$22.35$9.10▼$35.80$292.11M2.87392,073 shs3.08 million shsGALTGalectin Therapeutics$4.97-0.4%$2.55$2.03▼$7.13$327.32M0.47915,842 shs6.47 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%+6.04%-4.32%-0.59%+26.62%CYPHCypherpunk Technologies0.00%-13.72%-43.56%+1.97%+143.81%FBRXForte Biosciences0.00%+17.82%+10.28%-20.10%+71.67%GALTGalectin Therapeutics0.00%+75.62%+97.22%+93.39%+113.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 2.25Hold$7.50194.70% UpsideCYPHCypherpunk Technologies 1.00SellN/AN/AFBRXForte Biosciences 2.50Moderate Buy$67.00218.59% UpsideGALTGalectin Therapeutics 2.00Hold$11.00121.33% UpsideCurrent Analyst Ratings BreakdownLatest CYPH, ACIU, GALT, and FBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/23/2026GALTGalectin Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.006/18/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D-)5/8/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026ACIUAC Immune BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/22/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/21/2026GALTGalectin Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$3.70M69.97N/AN/A$0.54 per share4.71CYPHCypherpunk TechnologiesN/AN/AN/AN/A$1.83 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$4.71 per shareN/AGALTGalectin TherapeuticsN/AN/AN/AN/A($1.99) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$85.03M-$0.82N/A14.97N/A-1,788.02%-125.26%-40.85%8/4/2026 (Estimated)CYPHCypherpunk Technologies$4.82M-$0.02N/AN/AN/AN/A-48.33%-42.21%N/AFBRXForte Biosciences-$69.38M-$4.64N/AN/AN/AN/A-106.17%-85.50%8/13/2026 (Estimated)GALTGalectin Therapeutics-$30.84M-$0.41N/AN/AN/AN/AN/A-164.69%8/13/2026 (Estimated)Latest CYPH, ACIU, GALT, and FBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026GALTGalectin Therapeutics-$0.06-$0.08-$0.02-$0.08N/AN/A5/14/2026Q1 2026CYPHCypherpunk Technologies-$0.0406-$0.46-$0.4194-$0.46N/AN/A5/11/2026Q1 2026FBRXForte Biosciences-$1.16-$1.24-$0.08-$1.24N/AN/A4/30/2026Q1 2026ACIUAC Immune-$0.20-$0.19+$0.01-$0.19$0.33 million$1.40 million3/31/2026Q4 2025FBRXForte Biosciences-$1.42-$1.45-$0.03-$1.45N/AN/A3/31/2026Q4 2025GALTGalectin Therapeutics-$0.10-$0.08+$0.02-$0.08$36.32 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ACYPHCypherpunk TechnologiesN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC Immune0.110.871.02CYPHCypherpunk TechnologiesN/A27.2827.28FBRXForte BiosciencesN/A2.752.75GALTGalectin TherapeuticsN/A2.152.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%CYPHCypherpunk Technologies30.46%FBRXForte Biosciences77.63%GALTGalectin Therapeutics11.68%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%CYPHCypherpunk Technologies3.50%FBRXForte Biosciences4.40%GALTGalectin Therapeutics52.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140101.77 million97.09 millionOptionableCYPHCypherpunk Technologies40106.46 million102.74 millionOptionableFBRXForte Biosciences513.89 million13.28 millionOptionableGALTGalectin Therapeutics965.86 million31.22 millionOptionableCYPH, ACIU, GALT, and FBRX HeadlinesRecent News About These CompaniesGalectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 7,557 SharesJune 26 at 6:21 AM | insidertrades.comGalectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 UpsideJune 24, 2026 | seekingalpha.comGALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASHJune 24, 2026 | zacks.comGALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trialJune 23, 2026 | msn.comGalectin Therapeutics Reaches FDA Agreement on Phase 3 Endpoint and Regulatory Path for Belapectin Full ApprovalJune 23, 2026 | quiverquant.comQGalectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal HypertensionJune 23, 2026 | globenewswire.comGalectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH CirrhosisMay 27, 2026 | markets.businessinsider.comGalectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH CirrhosisMay 27, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)May 16, 2026 | theglobeandmail.comGalectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business UpdateMay 15, 2026 | globenewswire.comGalectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of HepatologyMay 11, 2026 | globenewswire.comGalectin Therapeutics, Inc. Investigated by the Portnoy Law FirmApril 27, 2026 | globenewswire.comGalectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?April 3, 2026 | zacks.comGalectin Therapeutics Reports 2025 Financial Results and Provides Business UpdateMarch 31, 2026 | markets.businessinsider.comFinancial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)March 27, 2026 | defenseworld.netDGalectin Therapeutics Inc.: Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.March 17, 2026 | finanznachrichten.deGalectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.March 17, 2026 | markets.businessinsider.comGalectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension TranscriptMarch 10, 2026 | seekingalpha.comGalectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and ...February 26, 2026 | markets.businessinsider.comGalectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALTFebruary 22, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYPH, ACIU, GALT, and FBRX Company DescriptionsAC Immune NASDAQ:ACIU$2.54 -0.02 (-0.59%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$2.54 0.00 (0.00%) As of 08:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Cypherpunk Technologies NASDAQ:CYPH$0.64 +0.02 (+3.12%) As of 06/26/2026 03:57 PM EasternLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Forte Biosciences NASDAQ:FBRX$21.03 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$22.28 +1.25 (+5.92%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Galectin Therapeutics NASDAQ:GALT$4.97 -0.02 (-0.40%) As of 06/26/2026 03:57 PM EasternGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback Winnebago Misses Estimates, But Surges 14% After Earnings 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
